Company / PP&E (Net)
Candel Therapeutics, Inc. PP&E (Net) History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$3.2M
FY2023
5-year range
$3.2M / $4.4M
FY2021-FY2023
Trend
-27.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $4M to $3M over the past 2 years.
Based on SEC 10-K filings.
$3M in FY2023.
Declined from $4M to $3M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, pp&e (net) decreased 27.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2023 | $3.2M | -27.5% |
| FY2022 | $4.4M | +15.3% |
| FY2021 | $3.8M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026